Perioperative tislelizumab improves survival in resectable NSCLC – a new standard of care?
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Cabozantinib plus atezolizumab may represent a novel option for patients progressing on first-line hormonal therapy
In the period 2024-2026, the technical collaboration between the United Nations agency and the Society plans a series of evidence-based activities to improve global cancer care
A phase II trial reports a longer recurrence-free and distant-metastasis free survival with the combination of mRNA and pembrolizumab.
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
A study identifies some altered inflammatory genes and pathways in non-small cell lung cancer that may be potential targets for overcoming acquired immune resistance
Acquired genomic changes, decreased TILs and HLA class I expression were identified in patients with non-small cell lung cancer progressing on immune checkpoint inhibitors
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.